Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy

Journal of Diabetes and its Complications

Volumn 22, Issue 2, 2008, Pages 137-143

  Dai, Hong Yan ^a,b   Guo, Xin Gui ^b   Ge, Zhi Ming ^a   Li, Zhen Hua ^a   Yu, Xiao Jing ^c   Tang, Meng Xiong ^a   Zhang, Yun ^a  

^a Qilu Hospital of Shandong University   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac remodeling; Diabetic cardiomyopathy; Urotensin II

Indexed keywords

MESSENGER RNA; RECEPTOR; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENDOTHELIUM CELL; FIBROBLAST; GENE EXPRESSION; HEART MUSCLE; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GENE EXPRESSION REGULATION; HEART DISEASES; MALE; MYOCARDIUM; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UROTENSINS;

EID: 39049141682     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2006.10.008     Document Type: Article

References (38)

1. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: A short review. Molecular and Cellular Biochemistry 261 (2004) 187-191
2. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
3. Bertoni A.G., Tsai A., Kasper E.K., and Brancati F.L. Diabetes and idiopathic cardiomyopathy: A nationwide case-control study. Diabetes Care 26 (2003) 2791-2795
4. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. British Journal of Pharmacology 135 (2002) 25-27
5. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. Journal of Molecular and Cellular Cardiology 41 (2006) 285-295
6. Chen S., Evans T., Mukherjee K., Karmazyn M., and Chakrabarti S. Diabetes-induced myocardial structural changes: Role of endothelin-1 and its receptors. Journal of Molecular and Cellular Cardiology 32 (2000) 1621-1629
7. Clozel M., Hess P., Qiu C., Ding S.S., and Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. Journal of Pharmacology and Experimental Therapeutics 316 (2006) 1115-1121
8. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. British Journal of Pharmacology 131 (2000) 1262-1274
9. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
10. Fiordaliso F., Li B., Latini R., Sonnenblick E.H., Anversa P., Leri A., and Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Laboratory Investigation 80 (2000) 513-527
11. Fischer V.W., Barner H.B., and Larose L.S. Pathomorphologic aspects of muscular tissue in diabetes mellitus. Human Pathology 15 (1984) 1127-1136
12. Hayat S.A., Patel B., Khattar R.S., and Malik R.A. Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clinical Science (London) 107 (2004) 539-557
13. Hileeto D., Cukiernik M., Mukherjee S., Evans T., Barbin Y., Downey D., Karmazyn M., and Chakrabarti S. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes/Metabolism Research and Reviews 18 (2002) 386-394
14. Hoenack C., and Rosen P. Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes 45 (1996) S82-S87
15. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., SarovBlat L., et al. Urotensin-UII-mediated cardiomyocytes hypertrophy: Effect of receptor antagonist and role of inflammatory mediators. Naunyn-Schmiedeberg's Archives of Pharmacology 370 (2004) 238-250
16. Khatter J.C., Sadri P., Zhang M., and Hoeschen R.J. Myocardial angiotensin II (Ang II) receptors in diabetic rats. Annals of the New York Academy of Sciences 793 (1996) 466-472
17. Kim S., Wanibuchi H., Hamaguchi A., Miura K., Yamanaka S., and Iwao H. Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension 30 (1997) 1054-1061
18. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., and Gilbert R.E. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. American Journal of Kidney Diseases 44 (2004) 826-831
19. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. International Journal of Cardiology 94 (2004) 93-97
20. LeWinter M.M. Diabetic cardiomyopathy: An overview. Coronary Artery Disease 7 (1996) 95-98
21. Mori Y., Otabe S., Dina C., Yasuda K., Populaire C., Lecoeur C., et al. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q and 20q and identifies two new candidates loci on 7p and 11p. Diabetes 51 (2002) 1247-1255
22. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
23. Ong K.L., Wong L.Y., Man Y.B., Leung R.Y., Song Y.Q., Lam K.S., and Cheung B.M. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27 (2006) 1659-1667
24. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
25. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology 30 (1972) 595-602
26. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., and Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. American Journal of Physiology. Heart and Circulatory Physiology 285 (2003) H1576-H1581
27. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. British Journal of Pharmacology 132 (2001) 5-9
28. Sechi L.A., Griffin C.A., and Schambelan M. The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 43 (1994) 1180-1184
29. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., and Marco J. Inhibition of insulin release by urotensin II-A study on the perfused rat pancreas. Hormone and Metabolic Research 33 (2001) 379-381
30. Spector K.S. Diabetic cardiomyopathy. Clinical Cardiology 21 (1998) 885-887
31. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clinical Science (London) 104 (2003) 1-5
32. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: Association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
33. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. Circulation Research 93 (2003) 246-253
34. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II on vascular smooth muscle cell proliferation. Journal of Hypertension 9 (2001) 2191-2196
35. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
36. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46 (2003) 972-976
37. Wolkart G., Stessel H., Saad Z., Kirchengast M., and Brunner F. Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase. British Journal of Pharmacology 148 (2006) 671-681
38. Zhang Y., Li J., Cao J., Chen J., Yang J., Zhang Z., et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart and Vessels 16 (2002) 64-68